LUND, SWEDEN--(Marketwired - April 15, 2013) - Active Biotech’s Annual Report 2012 (in Swedish) is now available for download at www.activebiotech.com. The English version will be available within short.
The Annual Report will only be digitally distributed.
Lund, April 15, 2013
Active Biotech AB (publ)
Tomas Leanderson President & CEO
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, tasquinimod for prostate cancer and ANYARA primarily for the treatment of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn’s and Lupus. The company also has one additional project in clinical development, the orally administered compound 57-57 for Systemic Sclerosis. Please visit www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 10:00 a.m. CET on April 15, 2013.
Annual Report 2012 Active Biotech AB (publ):
http://hugin.info/1002/R/1692964/556338.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
[HUG#1692964]
For further information, please contact:
Hans Kolam
CFO
Tel +46 (0)46 19 20 44
